After recording outbreaks of Candida auris in Latin American countries, the Sanitary Surveillance Agency (Anvisa) has published a risk statement on drug-resistant fungus.
The document gathers guidelines on how health services (hospitals, clinics, laboratories, among others) should proceed to prevent and control the spread of C. auris.
Among the main prevention measures are actions such as: emphasizing the importance of hand hygiene for all health professionals, visitors and companions, the availability of inputs for the correct hand hygiene and gloves and aprons for the management of the patient and their secretions, the correct arrangement to deal with the environment around the colonized patient or infected, among others.
The superfungo causes lethal infection and usually installs in people hospitalized with weakened immune systems.
Since 2017, Anvisa has received notifications of suspected cases of Candida auris, but, to date, no cases have been confirmed in national territory.
In the United States, the germ has infected nearly 600 people in recent years, including more than 300 patients in New York State.
Cases of infection have also been reported in Spain, Venezuela, India and Pakistan.
All Anvisa recommendations on Candida auris are available here.